Kaiser Washington Vaccine and Treatment Evaluation Unit

凯撒华盛顿疫苗和治疗评估单位

基本信息

  • 批准号:
    10493519
  • 负责人:
  • 金额:
    $ 31.49万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-05-11 至 2023-11-30
  • 项目状态:
    已结题

项目摘要

Abstract Infectious diseases continue to pose a significant threat to human health, with many types of infections having far-reaching, global consequences. The ability to develop vaccines, therapeutics, devices and diagnostics to prevent, treat, and identify infectious diseases is a critical public health need. Clinical trials are an integral component of these development efforts. Since the 1960s the Vaccine and Treatment Evaluation Units (VTEUs) have conducted trials that have evaluated promising vaccine and therapeutic candidates for infectious diseases such as influenza (including pandemic and avian influenza), malaria, tuberculosis, pneumococcal infection, in children and adults. In addition, the VTEUs have quickly launched trials in response to newly emerging and reemerging infectious diseases, such as the 2009 influenza H1N1 pandemic, and Waves 1 and 5 of the H7N9 avian influenza outbreaks in China. These efforts have provided data that informed public health policy. This proposal is in response to a new VTEU structure which will involve greater collaboration between the VTEUs, NIAID, and the newly formed Leadership Group structure that are all part of the NIAID Infectious Diseases Clinical Research Consortium (IDCRC). The IDCRC will enhance integration and efficiency of operations and, importantly, will foster the collaborative team science approaches now recognized as optimal to address important and complicated public health research priorities. Under the new cooperative agreement, the Kaiser Washington VTEU will continue to conduct clinical research and trials, including trials conducted under an IND or IDE, within the Kaiser Washington integrated care system to contribute to the priority research foci of NIAID. These priority areas include malaria, influenza and other respiratory infections, acute respiratory infections and include clinical trials, including human challenge models, and pharmacokinetic studies. The research will be conducted in collaboration with Seattle area infectious disease research partners who will provide scientific expertise, specialized facilities, and advanced immunologic laboratory capabilities. The Kaiser Washington VTEU will also develop and maintain surge capacity for clinical site, pharmacy and laboratory operations to enable the rapid initiation of clinical trials and other studies in response to emerging and reemerging infectious disease threats of public health importance.
摘要 传染病继续对人类健康构成重大威胁,许多类型的感染 影响深远的全球后果。开发疫苗、疗法、设备和诊断的能力 预防、治疗和识别传染病是一项重要的公共卫生需求。临床试验是一个整体 这些发展努力的组成部分。自20世纪60年代以来,疫苗和治疗评价单位 (VTEU)已经进行了试验,评估了有希望的传染病疫苗和治疗候选药物 流感(包括大流行和禽流感)、疟疾、结核病、肺炎球菌等疾病 感染,儿童和成人。此外,VTEU已迅速启动试验,以应对新的 新出现和再次出现的传染病,如2009年H1N1流感大流行和第一波和第二波 中国暴发的H7N9禽流感疫情中有5起。这些努力提供了为公众健康提供信息的数据 政策。 这项提议是对VTEU新结构的回应,该结构将涉及 VTEU、NIAID和新成立的领导班子结构都是NIAID传染病的一部分 疾病临床研究联盟(IDCRC)国际儿童权利公约“将提高综合和效率 运营,重要的是,将促进协作的团队科学方法,现在被认为是最佳的 处理重要而复杂的公共卫生研究优先事项。 根据新的合作协议,Kaiser Washington VTEU将继续进行临床研究 以及试验,包括在凯撒华盛顿综合保健系统内在IND或IDE下进行的试验 为NIAID的优先研究重点作出贡献。这些优先领域包括疟疾、流感和其他 呼吸道感染,急性呼吸道感染,包括临床试验,包括人类挑战模型, 和药代动力学研究。这项研究将与西雅图传染病地区合作进行。 疾病研究合作伙伴,将提供科学专业知识、专门设施和先进的 免疫学实验室能力。凯撒华盛顿VTEU也将发展并保持激增 临床现场、药房和实验室运营能力,以实现快速启动临床试验和 应对新出现和再次出现的传染病对公共卫生的重要威胁的其他研究。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

LISA A JACKSON其他文献

LISA A JACKSON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('LISA A JACKSON', 18)}}的其他基金

Kaiser Washington Vaccine and Treatment Evaluation Unit – DMID 21-0004
凯撒华盛顿疫苗和治疗评估单位 — DMID 21-0004
  • 批准号:
    10523479
  • 财政年份:
    2022
  • 资助金额:
    $ 31.49万
  • 项目类别:
Kaiser Washington Vaccine and Treatment Evaluation Unit
凯撒华盛顿疫苗和治疗评估单位
  • 批准号:
    10397719
  • 财政年份:
    2021
  • 资助金额:
    $ 31.49万
  • 项目类别:
Kaiser Washington Vaccine and Treatment Evaluation Unit - DMID 21-0012
凯撒华盛顿疫苗和治疗评估单位 - DMID 21-0012
  • 批准号:
    10414676
  • 财政年份:
    2021
  • 资助金额:
    $ 31.49万
  • 项目类别:
Kaiser Washington Vaccine and Treatment Evaluation Unit
凯撒华盛顿疫苗和治疗评估单位
  • 批准号:
    10403144
  • 财政年份:
    2021
  • 资助金额:
    $ 31.49万
  • 项目类别:
Kaiser Washington Vaccine and Treatment Evaluation Unit
凯撒华盛顿疫苗和治疗评估单位
  • 批准号:
    10403145
  • 财政年份:
    2021
  • 资助金额:
    $ 31.49万
  • 项目类别:
Kaiser Washington Vaccine and Treatment Evaluation Unit
凯撒华盛顿疫苗和治疗评估单位
  • 批准号:
    10493522
  • 财政年份:
    2021
  • 资助金额:
    $ 31.49万
  • 项目类别:
Kaiser Washington Vaccine and Treatment Evaluation Unit
凯撒华盛顿疫苗和治疗评估单位
  • 批准号:
    10493521
  • 财政年份:
    2021
  • 资助金额:
    $ 31.49万
  • 项目类别:
Kaiser Washington Vaccine and Treatment Evaluation Unit
凯撒华盛顿疫苗和治疗评估单位
  • 批准号:
    10493526
  • 财政年份:
    2021
  • 资助金额:
    $ 31.49万
  • 项目类别:
Kaiser Washington VTEU supplement 20-0003
凯撒华盛顿 VTEU 补充 20-0003
  • 批准号:
    10202069
  • 财政年份:
    2020
  • 资助金额:
    $ 31.49万
  • 项目类别:
Kaiser Washington Vaccine and Treatment Evaluation Unit
凯撒华盛顿疫苗和治疗评估单位
  • 批准号:
    10265732
  • 财政年份:
    2019
  • 资助金额:
    $ 31.49万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 31.49万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 31.49万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 31.49万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 31.49万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 31.49万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 31.49万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 31.49万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 31.49万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 31.49万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 31.49万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了